

Why carry out this study?

- Patients with type 2 diabetes escalating from metformin monotherapy to metformin and sulfonylurea dual therapy may be at increased risk of weight gain.
- The objectives of this study were to assess the factors associated with weight gain in this commonly observed population, and evaluate whether healthcare resource utilisation associated with being overweight or obese is underestimated.

What was learned from the study?

- Data analysed from UK clinical practice estimate there are identifiable patient characteristics predictive of weight gain.
- Type 2 diabetes models used to inform healthcare decision-making may under-predict hospital admissions related to weight gain compared to observed rates of admissions.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Takeda Development Centre Europe Ltd, UK. For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).